Comparing Black and White Patients in Treatment of Advanced Prostate Cancer and Survival in an Equal Access Health System

被引:0
|
作者
Eaglehouse, Yvonne L. [1 ,2 ]
Darmon, Sarah [1 ,2 ]
Chesnut, Gregory T. [1 ]
Shriver, Craig D. [1 ,3 ]
Zhu, Kangmin [1 ,2 ,4 ]
机构
[1] Uniformed Serv Univ Hlth Sci USUHS, Murtha Canc Ctr Res Program, Dept Surg, 6720A Rockledge Dr,Suite 310, Bethesda, MD 20817 USA
[2] Henry M Jackson Fdn Advancement Mil Med Inc, Bethesda, MD 20817 USA
[3] Walter Reed Natl Mil Med Ctr, Dept Surg, Bethesda, MD USA
[4] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Prevent Med & Biostat, Bethesda, MD 20814 USA
关键词
Prostate cancer; Cancer treatment; Racial disparities; Prostate cancer survival; Surgical oncology; MEN;
D O I
10.1007/s40615-024-02217-4
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
BackgroundRacial disparities in prostate cancer treatment and survival in the U.S. have been attributed to differences in access to care and medical insurance. We aimed to compare treatment and survival of advanced prostate cancers between White and Black men in the equal access Military Health System (MHS).MethodsWe accessed the MilCanEpi database to study a cohort of non-Hispanic White and Black men diagnosed with stage III or IV prostate cancer between 1998 and 2014 in the MHS. The racial groups were compared in receiving curative treatment of radical prostatectomy (RP) only, RP with (neo)adjuvant radiation or hormone therapy, radiation only, or combination radiation and hormone therapy; and overall survival using multivariable regression models.ResultsThe study included 1476 White and 531 Black men. Overall, there was no racial difference in receiving any curative treatment (AOR = 0.85, 95% CI = 0.67, 1.08 for Black vs. White). By treatment type, Black men were statistically as likely to receive RP only (AOR = 0.87, 95% CI = 0.67, 1.14), radiation only (AOR = 0.81, 95% CI = 0.49, 1.34), or combination radiation and hormone therapy (AOR = 1.12, 95% CI = 0.71, 1.78) but statistically less likely to receive RP with (neo)adjuvant treatment (AOR = 0.56, 95% CI = 0.37, 0.86) relative to no curative treatment compared to White men. The difference in RP with (neo)adjuvant treatment was also statistically significant among patients with stage III tumors, but not stage IV. Survival was similar overall (AHR = 1.12, 95% CI = 0.88, 1.42 for Black vs. White) and when evaluated by tumor stage.ConclusionsIn the MHS, the overall likelihood to receive any treatment for advanced prostate cancers and survival was similar between races, which might result from universal health care. Racial differences in receipt of RP with (neo)adjuvant treatment, especially for patients with stage III prostate cancer, may be related to factors other than access to care and warrants further research.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Lung Cancer Survival among Black and White Patients in an Equal Access Health System
    Zheng, Li
    Enewold, Lindsey
    Zahm, Shelia H.
    Shriver, Craig D.
    Zhou, Jing
    Marrogi, Aizen
    McGlynn, Katherine A.
    Zhu, Kangmin
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2012, 21 (10) : 1841 - 1847
  • [2] Comparison of Black and White patients in treatment for papillary thyroid cancer in an equal access health system
    Eaglehouse, Yvonne L.
    Darmon, Sarah
    Shriver, Craig D.
    Zhu, Kangmin
    CANCER RESEARCH, 2024, 84 (06)
  • [3] Overall and recurrence-free survival among black and white bladder cancer patients in an equal-access health system
    Schinkel, Jill K.
    Shao, Stephanie
    Zahm, Shelia H.
    McGlynn, Katherine A.
    Shriver, Craig D.
    Zhu, Kangmin
    CANCER EPIDEMIOLOGY, 2016, 42 : 154 - 158
  • [4] Experience with the US health care system for Black and White patients with advanced prostate cancer
    Rencsok, Emily H.
    Stopsack, Konrad
    Slopen, Natalie T.
    Odedina, Folakemi
    Ragin, Camille
    Nowak, Joel
    McSwain, Lawrence
    Manarite, Jan
    Heath, Elisabeth J.
    George, Daniel W.
    Kantoff, Philip
    Vinson, Jacob
    Villanti, Paul
    Haneuse, Sebastien A.
    Mucci, Lorelei
    IRONMAN Registry
    CANCER, 2023, 129 (16) : 2532 - 2541
  • [5] Survival among Black and White patients with renal cell carcinoma in an equal-access health care system
    Jie Lin
    Shelia H. Zahm
    Craig D. Shriver
    Mark Purdue
    Katherine A. McGlynn
    Kangmin Zhu
    Cancer Causes & Control, 2015, 26 : 1019 - 1026
  • [6] Survival among Black and White patients with renal cell carcinoma in an equal-access health care system
    Lin, Jie
    Zahm, Shelia H.
    Shriver, Craig D.
    Purdue, Mark
    McGlynn, Katherine A.
    Zhu, Kangmin
    CANCER CAUSES & CONTROL, 2015, 26 (07) : 1019 - 1026
  • [7] Survival of African American and non-Hispanic white men with prostate cancer in an equal-access health care system
    Riviere, Paul
    Luterstein, Elaine
    Kumar, Abhishek
    Vitzthum, Lucas K.
    Deka, Rishi
    Sarkar, Reith R.
    Bryant, Alex K.
    Bruggeman, Andrew
    Einck, John P.
    Murphy, James D.
    Martinez, Elena
    Rose, Brent S.
    CANCER, 2020, 126 (08) : 1683 - 1690
  • [8] Clinical characteristics in black and white men with prostate cancer in an equal access medical center
    Freedland, SJ
    Sutter, ME
    Naitoh, J
    Dorey, F
    Csathy, GS
    Aronson, WJ
    UROLOGY, 2000, 55 (03) : 387 - 390
  • [9] Race Does Not Impact Pancreatic Cancer Treatment and Survival in an Equal Access Federal Health Care System
    Lee, S.
    Jeffrey, R. L.
    Tzeng, C. D.
    Chang, G. J.
    Hetz, S. P.
    Fleming, J. B.
    Lee, J. E.
    Katz, M. H.
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 : S28 - S28
  • [10] Race Does Not Impact Pancreatic Cancer Treatment and Survival in an Equal Access Federal Health Care System
    Sukhyung Lee
    Jeffrey L. Reha
    Ching-Wei D. Tzeng
    Nader N. Massarweh
    George J. Chang
    Stephen P. Hetz
    Jason B. Fleming
    Jeffrey E. Lee
    Matthew H. Katz
    Annals of Surgical Oncology, 2013, 20 : 4073 - 4079